Pfizer is recovering from post-COVID and LOE-driven declines, with recent earnings beats and an attr

https://youtu.be/H_RititNE8U

Impairment charges crippled Pfizer's recent earnings. The company's free cash flow, however, remains

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and pate

Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound.

Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and lowers the price target

As Pfizer Inc. (NYSE: PFE) stock gained over 5% this week fueled by its strong second quarter 2026 e

Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) refreshed the dividend debate with the

Pfizer shares edged higher after Q2 earnings, shrugging off criticism over the discontinuation of tw

Second-quarter earnings season shook loose some rare discounts on five high-yield dividend stocks th

Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 m

PFE raises its 2026 revenue outlook as non-COVID growth, deeper cost cuts and pipeline catalysts off

Pfizer NYSE: PFE reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings p

Market sentiment improves, Dow Jones jumps 900 points to record high. Crude oil prices fall on poten

Pfizer Inc. (PFE) Q2 2026 Earnings Call Transcript

Pfizer stock rises after beating Q2 estimates and raising its 2026 revenue guidance to up to $62.5B.

Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lo

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed i

Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results a

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 700 points on Tue

Dow rises 1.35% with technology sector leading market gains. Pfizer beats Q2 earnings expectations.

Pfizer (PFE) came out with quarterly earnings of $0.77 per share, beating the Zacks Consensus Estima

U.S. stock futures edged higher on Tuesday, with Dow, S&P 500 and Nasdaq 100 futures advancing a

Pfizer swung to a second-quarter loss but posted higher revenue, as market growth in its oncology bu

Pfizer reported second-quarter results that topped estimates and hiked the low end of its revenue ou

Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations d

Pfizer beat Wall ​Street estimates for ‌second-quarter profit on Tuesday, ​driven by ​strong demand

Pfizer (NYSE:PFE) reported quarterly earnings of $0.77 per share which beat the analyst consensus es

Pfizer (NYSE:PFE) affirms FY2026 Adj EPS guidance from $2.80-$3.00 to $2.80-$3.00 vs $2.95 analyst e

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter

Fear & Greed Index improves, Dow Jones hits record high, oil prices fall after Trump's Iran

With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab inv

Stocks to watch today: Caterpillar, Palantir, McDonald's, Snap, Pfizer. Positive Q2 earnings rep

Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results a

Pfizer (PFE) will release Q2 earnings on Aug. 4, expected to report lower EPS of 68 cents and revenu

Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfiz

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation

Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global

Phase 3 trials evaluated the efficacy and safety of LITFULO once daily in patients with both active

The formula targets the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Rep. Thomas Massie questions JD Vance's silence after the Trump CDC established a $1.24 Billion

A Premarin shortage in India leaves menopausal patients facing limited treatment options as Pfizer h

Sen. Tommy Tuberville is cashing out of stocks in 2026. Here's the list.

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce

BMO Capital analyst Evan David Seigerman maintains Pfizer (NYSE:PFE) with a Outperform and lowers

Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and lowers the price target

B of A Securities analyst Jason Gerberry maintains Pfizer (NYSE:PFE) with a Neutral and lowers th

FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backe